Japanese Vaccine Maker Biken To Invest ¥35 Billion To Establish New Flu Vaccine Facility
This article was originally published in PharmAsia News
Executive SummaryThe Research Foundation for Microbial Disease of Osaka University (Biken) will establish a new vaccine production facility in Kagawa Prefecture. Biken plans to invest ¥35 billion to build the research and manufacturing complex in a 160,000 square foot area. To be completed in 2013, the facility will be able to manufacture flu vaccines for half of Japan's population (60 million) in six months. Biken uses dog kidney cells to culture virus, which cuts the current one year production time in half. (Click here for more - Japanese language)
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.